Abiopharma

🔍 NORA JOHNSON SUZANNE M (Director)

Company: NVIDIA CORP (NVDA)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Acquired 1,262 shares of Common Stock (Direct)
  Date: 2026-08-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,262.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,148 shares of Common Stock (Direct)
  Date: 2026-08-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,410.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-10 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 2,496.00 | Footnotes: F3

Footnotes:

• F1: Initial grant in connection with appointment to the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock unit shall vest as to 1/6th of the shares on March 17, 2027 and 1/6th of the shares approximately every six months thereafter, such that the shares are fully vested on approximately the three (3) year anniversary of the date of grant. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested.
• F2: Pro-rated annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock unit shall vest as to 543 shares on November 18, 2026 and 605 shares on May 19, 2027. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested.
• F3: Shares are held by a family trust, of which the Reporting Person and her spouse are cotrustees.